Thongcharoen, P., Suriyanon, V., Paris, R. M., Khamboonruang, C., Souza, M. S. D., Ratto-Kim, S., . . . Kim, J. H. (2018). A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.
Chicago Style CitationThongcharoen, Prasert, et al. A Phase 1/2 Comparative Vaccine Trial of the Safety and Immunogenicity of a CRF01_AE (subtype E) Candidate Vaccine: ALVAC-HIV (vCP1521) Prime With Oligomeric Gp160 (92TH023/LAI-DID) or Bivalent Gp120 (CM235/SF2) Boost. 2018.
MLA CitationThongcharoen, Prasert, et al. A Phase 1/2 Comparative Vaccine Trial of the Safety and Immunogenicity of a CRF01_AE (subtype E) Candidate Vaccine: ALVAC-HIV (vCP1521) Prime With Oligomeric Gp160 (92TH023/LAI-DID) or Bivalent Gp120 (CM235/SF2) Boost. 2018.